(Q37672600)

21 August 2017

1 reference

title

Effect of obesity on the pharmacokinetics of drugs in humans (English)

1 reference

21 August 2017

0 references

1 reference

3

David J Greenblatt

1 reference

21 August 2017

2

Darrell R Abernethy

1 reference

21 August 2017

Michael J Hanley

1

1 reference

21 August 2017

publication date

1 January 2010

1 reference

Clinical Pharmacokinetics

21 August 2017

published in

1 reference

21 August 2017

volume

49

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

71-87

1 reference

Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults

21 August 2017

cites work

1 reference

12 December 2020

Obesity in children and young people: a crisis in public health

1 reference

12 December 2020

The impact of obesity and disease on busulfan oral clearance in adults

1 reference

12 December 2020

A formula to estimate the approximate surface area if height and weight be known. 1916.

1 reference

12 December 2020

Pharmacokinetic considerations in obesity

1 reference

12 December 2020

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

1 reference

12 December 2020

Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate).

1 reference

12 December 2020

Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model

1 reference

12 December 2020

Serum alpha 1-acid glycoprotein and the binding of drugs in obesity

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis

1 reference

12 December 2020

The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients

1 reference

12 December 2020

Development of a dosing strategy for enoxaparin in obese patients

1 reference

12 December 2020

Pharmacokinetics of drugs in obesity

1 reference

12 December 2020

Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen

1 reference

12 December 2020

Human body composition: in vivo methods

1 reference

12 December 2020

Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers

1 reference

12 December 2020

Low-molecular-weight heparins

1 reference

12 December 2020

Simplified calculation of body-surface area.

1 reference

12 December 2020

The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.

1 reference

12 December 2020

Phenytoin disposition in obesity. Determination of loading dose

1 reference

12 December 2020

Caution when lean body weight is used as a size descriptor for obese subjects

1 reference

12 December 2020

Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity.

1 reference

12 December 2020

Skinfold thickness measurements in obese subjects

1 reference

12 December 2020

Obesity, sex, and acetaminophen disposition

1 reference

12 December 2020

Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

1 reference

12 December 2020

The effects of cisatracurium on morbidly obese women

1 reference

12 December 2020

Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects

1 reference

12 December 2020

Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia

1 reference

12 December 2020

Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections

1 reference

12 December 2020

A standard weight descriptor for dose adjustment in the obese patient

1 reference

12 December 2020

Dosage of enoxaparin among obese and renal impairment patients

1 reference

12 December 2020

Obese man treated with drotrecogin alfa (activated)

1 reference

12 December 2020

The effect of body weight on dalteparin pharmacokinetics. A preliminary study

1 reference

12 December 2020

Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual

1 reference

12 December 2020

Quantification of lean bodyweight.

1 reference

12 December 2020

Clinical pharmacokinetics of drugs in obesity. An update

1 reference

12 December 2020

Drug disposition in obese humans. An update

1 reference

12 December 2020

Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis

1 reference

12 December 2020

Bioelectrical impedance analysis--part I: review of principles and methods

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

1 reference

12 December 2020

Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children

1 reference

12 December 2020

Quantification of doxorubicin in plasma--a comparative study of capillary and venous blood sampling

1 reference

12 December 2020

Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey

1 reference

12 December 2020

Glimepiride pharmacokinetics in obese versus non-obese diabetic patients

1 reference

12 December 2020

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

1 reference

12 December 2020

Impairment of hepatic microcirculation in fatty liver

1 reference

12 December 2020

What is the best size descriptor to use for pharmacokinetic studies in the obese?

1 reference

12 December 2020

Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study

1 reference

12 December 2020

The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects

1 reference

12 December 2020

In vivo pharmacodynamic activity of daptomycin

1 reference

12 December 2020

Cardiac remodeling in obesity.

1 reference

12 December 2020

Is Volume of Distribution at Steady State a Meaningful Kinetic Variable?

1 reference

12 December 2020

Body mass index, weight, and oral contraceptive failure risk

1 reference

12 December 2020

Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers

1 reference

12 December 2020

Keeping the young-elderly healthy: is it too late to improve our health through nutrition?

1 reference

12 December 2020

Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers

1 reference

12 December 2020

Body weight and risk of oral contraceptive failure

1 reference

12 December 2020

Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection

1 reference

12 December 2020

A review of in vivo experimental methods to determine the composition of the human body

1 reference

12 December 2020

Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study

1 reference

12 December 2020

Linezolid pharmacokinetics in an obese patient.

1 reference

12 December 2020

Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina

1 reference

12 December 2020

Global burden of obesity in 2005 and projections to 2030.

1 reference

12 December 2020

Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity.

1 reference

12 December 2020

Nonalcoholic Fatty liver disease and obesity

1 reference

12 December 2020

Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects

1 reference

12 December 2020

CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers

1 reference

12 December 2020

Body-composition assessment via air-displacement plethysmography in adults and children: a review

1 reference

12 December 2020

Dual-energy X-ray absorptiometry body composition model: review of physical concepts

1 reference

12 December 2020

Pharmacokinetics and Pharmacodynamics of Triazolam After Two Intermittent Doses in Obese and Normal-Weight Men

1 reference

12 December 2020

A comparative pharmacokinetic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure.

1 reference

12 December 2020

Comment: obese man treated with drotrecogin alfa (activated).

1 reference

12 December 2020

Pharmacokinetics of quinine in obesity

1 reference

12 December 2020

Pharmacokinetics of rocuronium bromide in obese female patients.

1 reference

12 December 2020

Effects of obesity on pharmacokinetics implications for drug therapy

1 reference

12 December 2020

Intravenous ciprofloxacin disposition in obesity

1 reference

12 December 2020

1 reference

12 December 2020

Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin

1 reference

12 December 2020

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese

1 reference

12 December 2020

Epidemiologic and economic consequences of the global epidemics of obesity and diabetes

1 reference

12 December 2020

Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

12 December 2020

Obesity and diabetes in the developing world--a growing challenge

1 reference

12 December 2020

Prolonged accumulation of diazepam in obesity.

1 reference

12 December 2020

Influence of lean body weight on anticancer drug clearance

1 reference

12 December 2020

Dosing in obesity: a simple solution to a big problem.

1 reference

12 December 2020

Volume of Distribution as a Function of Time

1 reference

12 December 2020

Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541

1 reference

12 December 2020

10.2165/11318100-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

1040691762

0 references

1 reference